食管鳞状细胞癌的辅助治疗
Adjuvant Therapy for Esophageal Squamous Cell Carcinoma.
作者信息
Sun Jong-Mu
机构信息
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
出版信息
Korean J Thorac Cardiovasc Surg. 2020 Aug 5;53(4):168-171. doi: 10.5090/kjtcs.2020.53.4.168.
Abstract
Adjuvant therapy for completely resected esophageal squamous cell carcinoma is less commonly applied in clinical practice than neoadjuvant therapy, but it plays a substantial role in improving survival for esophageal cancer patients. This article presents a concise review of the evidence regarding adjuvant therapy for esophageal squamous cell carcinoma and future directions, particularly immunotherapy.
摘要
与新辅助治疗相比，辅助治疗在完全切除的食管鳞状细胞癌临床实践中的应用较少，但它在提高食管癌患者生存率方面发挥着重要作用。本文简要综述了食管鳞状细胞癌辅助治疗的相关证据及未来方向，特别是免疫治疗。
相似文献
1
Adjuvant Therapy for Esophageal Squamous Cell Carcinoma.食管鳞状细胞癌的辅助治疗
Korean J Thorac Cardiovasc Surg. 2020 Aug 5;53(4):168-171. doi: 10.5090/kjtcs.2020.53.4.168.
2
Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience.II-III期食管鳞状细胞癌新辅助与辅助放化疗：单机构经验
Dis Esophagus. 2017 Jul 1;30(7):1-7. doi: 10.1093/dote/dox016.
3
Evaluation of the 7th edition of the TNM classification in patients with resected esophageal squamous cell carcinoma.对接受手术切除的食管鳞状细胞癌患者进行第7版TNM分类评估。
World J Gastroenterol. 2014 Dec 28;20(48):18397-403. doi: 10.3748/wjg.v20.i48.18397.
4
Clinical significance of plasma fibrinogen level as a predictive marker for postoperative recurrence of esophageal squamous cell carcinoma in patients receiving neoadjuvant treatment.血浆纤维蛋白原水平作为接受新辅助治疗的食管鳞状细胞癌患者术后复发预测标志物的临床意义
Dis Esophagus. 2014 Sep-Oct;27(7):654-61. doi: 10.1111/dote.12115. Epub 2013 Aug 27.
5
Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.临床III期食管鳞状细胞癌患者新辅助化疗与先行手术加或不加化疗的比较。
Dis Esophagus. 2017 Feb 1;30(2):1-8. doi: 10.1111/dote.12473.
6
Survival outcomes of resected patients who demonstrate a pathologic complete response after neoadjuvant chemoradiation therapy for locally advanced esophageal cancer.接受新辅助放化疗后病理完全缓解的局部晚期食管癌切除患者的生存结果。
Dis Esophagus. 2006;19(2):69-72. doi: 10.1111/j.1442-2050.2006.00542.x.
7
Prognostic implications of and status in esophageal squamous cell carcinoma.食管鳞状细胞癌中[具体内容]和[具体内容]状态的预后意义。 （原文中两个“and”之间缺失关键信息）
World J Gastroenterol. 2016 Nov 28;22(44):9803-9812. doi: 10.3748/wjg.v22.i44.9803.
8
Removal of tumor thrombus from the azygos vein in an esophageal squamous cell carcinoma patient.一名食管鳞状细胞癌患者奇静脉肿瘤血栓的清除。
J Cardiothorac Surg. 2020 Mar 26;15(1):52. doi: 10.1186/s13019-020-01092-4.
9
Survival After Neoadjuvant and Adjuvant Treatments Compared to Surgery Alone for Resectable Esophageal Carcinoma: A Network Meta-analysis.新辅助和辅助治疗与单纯手术治疗可切除食管癌的生存率比较：一项网状Meta分析。
Ann Surg. 2017 Mar;265(3):481-491. doi: 10.1097/SLA.0000000000001905.
10
Effects of neoadjuvant radiochemotherapy on pathological staging and prognosis for locally advanced esophageal squamous cell carcinoma.新辅助放化疗对局部晚期食管鳞状细胞癌病理分期及预后的影响。
Dis Esophagus. 2009;22(6):477-81. doi: 10.1111/j.1442-2050.2008.00910.x.
本文引用的文献
1
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.纳武利尤单抗对比化疗用于既往化疗后进展或不耐受的晚期食管鳞癌患者（ATTRACTION-3）：一项多中心、随机、开放标签、III 期临床研究。
Lancet Oncol. 2019 Nov;20(11):1506-1517. doi: 10.1016/S1470-2045(19)30626-6. Epub 2019 Sep 30.
2
Predicting the Value of Adjuvant Therapy in Esophageal Squamous Cell Carcinoma by Combining the Total Number of Examined Lymph Nodes with the Positive Lymph Node Ratio.通过结合检查的淋巴结总数和阳性淋巴结比值来预测食管鳞癌辅助治疗的价值。
Ann Surg Oncol. 2019 Aug;26(8):2367-2374. doi: 10.1245/s10434-019-07489-3. Epub 2019 Jun 11.
3
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.度伐利尤单抗化疗和放疗后用于 III 期非小细胞肺癌的总生存。
N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25.
4
Efficacy of postoperative adjuvant chemotherapy for esophageal squamous cell carcinoma: A meta-analysis.术后辅助化疗治疗食管鳞状细胞癌的疗效：一项荟萃分析。
Thorac Cancer. 2018 Aug;9(8):1048-1055. doi: 10.1111/1759-7714.12787. Epub 2018 Jun 21.
5
Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial.纳武利尤单抗治疗食管鳞癌：一项开放标签、多中心、2 期临床试验。
Lancet Oncol. 2017 May;18(5):631-639. doi: 10.1016/S1470-2045(17)30181-X. Epub 2017 Mar 15.
6
A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma.亚叶酸钙/5-氟尿嘧啶联合或不联合奥沙利铂（LV5FU2对比FOLFOX）用于根治性切除的、淋巴结阳性食管鳞状细胞癌的随机II期研究。
Cancer Res Treat. 2017 Jul;49(3):816-823. doi: 10.4143/crt.2016.417. Epub 2016 Nov 9.
7
Utility of Adjuvant Chemotherapy After Neoadjuvant Chemoradiation and Esophagectomy for Esophageal Cancer.新辅助放化疗和食管切除术后辅助化疗在食管癌中的应用。
Ann Surg. 2017 Aug;266(2):297-304. doi: 10.1097/SLA.0000000000001954.
8
Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses.比较卡培他滨和顺铂辅助化疗与同期放化疗治疗胃癌的 III 期临床试验：胃癌辅助放化疗临床试验的最终报告，包括生存和亚组分析。
J Clin Oncol. 2015 Oct 1;33(28):3130-6. doi: 10.1200/JCO.2014.58.3930. Epub 2015 Jan 5.
9
Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.食管癌：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2013 Oct;24 Suppl 6:vi51-6. doi: 10.1093/annonc/mdt342.
10
Preoperative chemoradiotherapy for esophageal or junctional cancer.术前放化疗治疗食管或食管胃交界癌。
N Engl J Med. 2012 May 31;366(22):2074-84. doi: 10.1056/NEJMoa1112088.
Zotero 插件